The news here is a clinical victory lap 🏆—high response rates in elderly DLBCL patients with Epcoritamab. This isn’t just noise; it’s a potential pipeline catalyst that trumps the technicals. The RSI is meandering in neutral (54), and the WMAs are flat, but the chart shows a clear breakout from a tight consolidation on June 26th, with volume spiking 38% above average. The market is waking up to the story. **BUY**—the fundamental momentum outweighs the sleepy moving averages. 📈 #PipelinePower

FDA just turbocharged their cancer portfolio with a new approval! 📈 The stock's shaking off its slump, with the 9-day WMA nudging past the 21-day. RSI is neutral, so there's room to run. This news is the real catalyst – institutions are buying the story. BUY the breakout. #BiotechBounce

GMAB's $8B acquisition is pure rocket fuel! 🚀 The stock ripped 21% this month, but now the technicals are catching their breath. RSI cooled from overbought 85 to a healthier 66, and it's pulling back to test support. This looks like a classic "buy the rumor, sell the news" dip. I'm buying this consolidation. The trend is still your friend. #MomentumMoment

Genmab's news flow is a rocket booster! 💪 Blockbuster trial results, a major upgrade, and Trump's drug price push are creating serious momentum. The stock is breaking above key averages, RSI is strong but not greedy, and volume confirms the move. This isn't just a squiggle on a chart; it's a story of strength. All signs point to a decisive BUY. #BiotechBull **Signal: BUY**